Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
(2023) In Blood Advances 7(5). p.866-874- Abstract
Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N = 620; treated with HD-ASCT, n = 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and... (More)
Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N = 620; treated with HD-ASCT, n = 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and Cause of Death Register, from 12 months after diagnosis or matching to December 2017. Incidence rate ratios of the numbers of outpatient visits, hospitalizations, and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among patients with MCL. Patients with MCL had especially high relative risks of infectious, respiratory, and blood disorders. Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. Most of the patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that most of the posttreatment health care needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options.
(Less)
- author
- Ekberg, Sara ; Smedby, Karin E. ; Albertsson-Lindblad, Alexandra LU ; Jerkeman, Mats LU ; Weibull, Caroline E. and Glimelius, Ingrid
- organization
- publishing date
- 2023-03-14
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood Advances
- volume
- 7
- issue
- 5
- pages
- 9 pages
- publisher
- American Society of Hematology
- external identifiers
-
- scopus:85150424455
- pmid:35973196
- ISSN
- 2473-9529
- DOI
- 10.1182/bloodadvances.2022007241
- language
- English
- LU publication?
- yes
- id
- 89e942d4-c623-4d6e-b305-cb4b502320dd
- date added to LUP
- 2023-05-05 08:22:18
- date last changed
- 2024-04-19 21:31:23
@article{89e942d4-c623-4d6e-b305-cb4b502320dd,
abstract = {{<p>Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. However, knowledge about late effects is limited. The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). The study cohort included all patients with MCL, recorded in the Swedish Lymphoma Register, aged 18 to 69 years, diagnosed between 2000 and 2014 (N = 620; treated with HD-ASCT, n = 247) and 1:10 matched healthy comparators. Patients and comparators were followed up via the National Patient Register and Cause of Death Register, from 12 months after diagnosis or matching to December 2017. Incidence rate ratios of the numbers of outpatient visits, hospitalizations, and bed days were estimated using negative binomial regression models. In relation to the matched comparators, the rate of specialist and hospital visits was significantly higher among patients with MCL. Patients with MCL had especially high relative risks of infectious, respiratory, and blood disorders. Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. Most of the patients died from their lymphoma and not from another cause or treatment complication. Taken together, our results imply that most of the posttreatment health care needs are related to the lymphoma disease itself, thus, indicating the need for more efficient treatment options.</p>}},
author = {{Ekberg, Sara and Smedby, Karin E. and Albertsson-Lindblad, Alexandra and Jerkeman, Mats and Weibull, Caroline E. and Glimelius, Ingrid}},
issn = {{2473-9529}},
language = {{eng}},
month = {{03}},
number = {{5}},
pages = {{866--874}},
publisher = {{American Society of Hematology}},
series = {{Blood Advances}},
title = {{Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation}},
url = {{http://dx.doi.org/10.1182/bloodadvances.2022007241}},
doi = {{10.1182/bloodadvances.2022007241}},
volume = {{7}},
year = {{2023}},
}